Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Terminated No phase listed Observational

AMEVIVE® Pregnancy Registry

NCT00342862
View directory record Official record
Conditions
Pregnancy
Interventions
Amevive exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 15, 2026, 7:05 PM EDT
Active, not recruiting Phase 4 Interventional

Romosozumab Use to Build Skeletal Integrity

NCT05058976
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions
Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Study of Ambrisentan in Participants With Pulmonary Hypertension

NCT00777920
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 15, 2026, 7:05 PM EDT
Recruiting No phase listed Observational

Histiocytic Disorder Follow-up Study

NCT05915208
View directory record Official record
Conditions
Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease, Xanthogranuloma, Malignant Histiocytoses
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
0 Years to 89 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vending Labeling Sales and Intercepts Study

NCT06260176
View directory record Official record
Conditions
Food Preferences, Obesity, Weight Gain
Interventions
exposure to healthy labels only, exposure to healthiness information, exposure to physical activity equivalents, exposure to sweetened beverage tax messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Phase 2Phase 3 Interventional

The ATLAST Long-Term Study

NCT01476917
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Attune Sleep Apnea System
Device
Lead sponsor
ApniCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Phoenix, Arizona • Burlingame, California • Menlo Park, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 15, 2026, 7:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy of the Bone-anchored Hearing Aid for Unilateral Deafness

NCT00201617
View directory record Official record
Conditions
Unilateral Deafness
Interventions
Bone-anchored hearing aid
Device
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 15, 2026, 7:05 PM EDT
Terminated Phase 2 Interventional

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

NCT05226780
View directory record Official record
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
NBI-921352
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Completed No phase listed Observational

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

NCT00085176
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 16 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 15, 2026, 7:05 PM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.

NCT02753075
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Fluoride toothpaste
Device · Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 15, 2026, 7:05 PM EDT
Recruiting Phase 4 Interventional

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

NCT07695701
View directory record Official record
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Interventions
Acoramidis (AG10) oral tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

NCT06910943
View directory record Official record
Conditions
Choline Deficiency, Liver Injury
Interventions
Choline Chloride for Injection, Placebo
Drug
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Miami Lakes, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640
View directory record Official record
Conditions
Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, Arizona • Phoenix, Arizona • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 15, 2026, 7:05 PM EDT
Withdrawn No phase listed Observational

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

NCT01085162
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

NCT02116803
View directory record Official record
Conditions
Solid Tumors
Interventions
dovitinib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Las Vegas, Nevada • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 15, 2026, 7:05 PM EDT
Completed No phase listed Observational

ATHN 11: Liver Transplantation Outcomes Study

NCT04055051
View directory record Official record
Conditions
Hemophilia A and B, Liver Transplantation
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 15, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)

NCT00094575
View directory record Official record
Conditions
Aortic Aneurysm
Interventions
Endovascular Repair, Standard Open Repair
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 15, 2026, 7:05 PM EDT
Terminated Not applicable Interventional

Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

NCT01033357
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Hyperplasia
Interventions
Graft, Vascular Wrap, Lifespan® ePTFE Vascular Graft Only
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Fresno, California • Inglewood, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 15, 2026, 7:05 PM EDT
Not yet recruiting Not applicable Interventional

Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients

NCT06874101
View directory record Official record
Conditions
COPD, COPD - Chronic Obstructive Pulmonary Disease
Interventions
Activated ROAM System with User Feedback, Sham Comparator
Device
Lead sponsor
Barron Associates, Inc.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 15, 2026, 7:05 PM EDT
Recruiting Phase 2 Interventional

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Interventions
AP01
Combination Product
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Recruiting Phase 2 Interventional

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

NCT06150417
View directory record Official record
Conditions
Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
Interventions
Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
Drug · Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 7:05 PM EDT
Completed No phase listed Observational Results available

Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

NCT00836589
View directory record Official record
Conditions
Patients Indicated for an ICD
Interventions
ICD Therapy - ICD Lead Registry
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
85
States / cities
Albertville, Alabama • Birmingham, Alabama • Gadsden, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 15, 2026, 7:05 PM EDT